RECRUITING

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Description

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

Conditions

Breast CancerHER2-negative Breast CancerNode-negative Breast CancerBreast Carcinoma
Talk to us

Related Conditions:

Breast CancerHER2-negative Breast CancerNode-negative Breast CancerBreast Carcinoma

Study Overview

On this page

Study Details

Study overview

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Lexington

University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States, 40536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pathologically confirmed invasive breast cancer, clinically stage I-II.
  • * Clinically lymph node negative
  • * Eligible for anti-endocrine treatment (per medical oncologist)
  • * Postmenopausal women
  • * Ability to understand and the willingness to sign a written informed consent document
  • * Progesterone receptor negativity
  • * High grade tumor
  • * Synchronous non-breast malignancy
  • * Receiving any other investigational agents that could impact the efficacy of this trial regimen
  • * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study
  • * Uncontrolled intercurrent illness
  • * Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Veronica Morgan Jones,

Veronica M Jones, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2036-10